Clinical trial Recruiting at 1 site Interventional Ages 18 to 80

Using a brain-computer interface to help people with tetraplegia communicate

Official title: Intuitive, Complete Neural Control of Tablet Computers for Communication

Run by Massachusetts General Hospital · NCT06511934 · Data updated 2026-11-12

This study is testing a new brain-computer interface to help people with tetraplegia communicate more easily using a tablet.

Quick facts

Study typeInterventional
Ages18 Years to 80 Years
SexAll
Enrollment6 (estimated)
SponsorMassachusetts General Hospital
Academic / other
Locations1 site (Boston, Massachusetts)
StatusRecruiting
StartedJuly 22, 2024
Main results expectedJuly 30, 2027
Study endsJuly 30, 2028
Registry record updatedOctober 26, 2026
Trial IDNCT06511934 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include individuals with complete or incomplete tetraplegia due to spinal cord injury, brainstem stroke, or motor neuron disorders.

Probably not a fit

Patients with severe visual impairments or those on chronic immunosuppressive therapy may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This project aims to enhance communication for individuals with tetraplegia by developing an intracortical brain-computer interface (iBCI) that allows intuitive control of communication applications on tablet computers. Participants with conditions such as brainstem stroke or ALS will be equipped with the BrainGate Neural Interface System to interpret brain signals related to movement. The study focuses on translating these signals into actionable commands for communication, thereby improving the quality of life for those affected by severe motor impairments.

Why it matters

Potential benefit: If successful, this technology could significantly improve communication abilities for patients with severe paralysis.

How similar studies have gone: Previous studies involving brain-computer interfaces have shown promise, indicating potential for success in this novel application.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Clinical diagnosis of spinal cord injury, brainstem stroke, muscular dystrophy, amyotrophic lateral sclerosis or other motor neuron disorders
* Complete or incomplete tetraplegia (quadriplegia)
* Must live within a three-hour drive of the Study site
* Prior enrollment in BrainGate2 clinical trial (NCT00912041)

Exclusion Criteria:

* Visual impairment such that extended viewing of a computer monitor would be difficult even with ordinary corrective lenses
* Chronic oral or intravenous steroids or immunosuppressive therapy
* Other serious disease or disorder that could seriously affect ability to participate in the study

(There are additional exclusion criteria)

Where it's running

  • Masssachusetts General Hospital
    Boston, Massachusetts, United States
    Recruiting

Study contacts

  • Principal investigator: Leigh R Hochberg, MD, Ph.D. — Massachusetts General Hospital
  • Study coordinator: Leigh R Hochberg, MD, Ph.D
  • Email: lhochberg@mgh.harvard.edu
  • Phone: 617-724-9247

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.